Lutetium-177
Lu-177 · Lutetium, Z = 71, A = 177
At 4.11e+15 Bq/g — 1.11e+5 Ci/g — a gigabecquerel of Lu-177 amounts to 243 ng, which is why activity rather than mass is how anyone states the quantity. Lutetium-177 decays by beta-minus emission with a half-life of 6.6443 days, falling to 48.18% of today's activity in a week and 7.5e-3% in three months.
The air kerma rate constant is small — 0.00410 mGy·m²/(GBq·h), 19× less than Cs-137 and 74× less than Co-60, ranking 77 of 96 by Γ — in the bottom quarter of the photon emitters, but above the cutoff, which 51 nuclides in this dataset are not. It takes 4.87 GBq at a metre to reach 20 µSv/h from the photons alone.
A half-value layer of 0.404 mm in lead puts this in foil and thin sheet, with 4.28 mm needed if the material is steel; ten-fold attenuation comes at 1.96 mm of lead. At 1 GBq and a metre the photon dose rate is already under 20 µSv/h with nothing in the way. The tenth-value layer runs 4.9 times the half-value layer, not the 3.32 a single energy would give.
The beta endpoint is 0.497 MeV, mean 0.134 MeV over 4 branches. That endpoint stops in 1.36 mm of acrylic or 0.649 mm of glass. Of the beta energy, 0.11% turns into X-rays in acrylic and 1.43% in lead.
Lu-177 in radioligand therapy
Lu-177 has become the leading nuclide of radioligand therapy: labelled somatostatin analogues treat neuroendocrine tumours, and labelled ligands of prostate-specific membrane antigen treat advanced prostate cancer. It emits a beta of medium energy that delivers the dose within a millimetre or two of tissue, and gamma lines that let the same treatment be imaged and its dose estimated. It is made in reactors either directly from lutetium enriched in Lu-176, which produces a long-lived isomer as a by-product, or indirectly from ytterbium, which gives no-carrier-added material.
Lu-176 captures neutrons so readily that direct irradiation gives a usable specific activity, but the unconverted lutetium remains as Lu-177 decays, so carrier-added material has a short shelf life for peptide labelling. The indirect route must instead extract a trace of lutetium from bulk ytterbium, which binds the same chelators. Lu-177m shares both imaging lines and its other lines are masked by fresh Lu-177, so it is measured on an aliquot left for several weeks.
Both imaging lines in the photon table are stopped by thin lead, as the shielding table shows, so patient rooms need only modest shielding, and the beta, whose range figures appear here, is absorbed in the patient. Most decays reach the hafnium ground state without a photon, hence the low dose rate; the lowest-energy table entries are hafnium K X-rays. The weak photon output is also why staff receive comparatively low doses when large therapeutic activities are prepared and given.
Calibrator readings for Lu-177 change with vial type and filling volume, so the calibration against a traceable standard should be done in the clinical geometry. Medium-energy collimators are preferred because they limit septal penetration, and with them the main window is centred on the upper photopeak, whose backscatter falls on the lower one. Quantitative SPECT gives the kidney and marrow doses some centres use to set the number of cycles; permanent kidney damage has been considerably less frequent with Lu-177 octreotate than with the earlier Y-90 octreotide.
Lu-177 decays slowly enough for a dose to be shipped internationally and fast enough for waste to decay within a few months; the isomer that accompanies the directly produced material lasts much longer and governs the disposal of that waste. Most of the activity leaves in urine, so where wards hold excreta in tanks, the isomer is what builds up.
- IAEA Live Chart of Nuclides (ENSDF decay data)
- LNHB / DDEP, Recommended nuclear data tables: Lu-177
- Dash, Pillai and Knapp, Production of 177Lu for Targeted Radionuclide Therapy: Available Options, Nuclear Medicine and Molecular Imaging (2015)
- Ljungberg et al., MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy, Journal of Nuclear Medicine (2016)
Half-life, specific activity, dose rate and beta energies
| Half-life | 6.6443 days (5.741e+5 s) |
| Decay mode | beta-minus decay |
| Specific activity | 4.11e+15 Bq/g (1.11e+5 Ci/g) |
| Air kerma rate constant Γ (δ = 20 keV) | 0.00410 mGy·m²/(GBq·h) |
| Dose rate, 1 GBq at 1 m | 0.00410 mGy/h |
| Dose rate, 1 Ci at 1 m | 0.152 mGy/h |
| Kerma-weighted mean photon energy | 175.5 keV |
| Beta endpoint / mean | 0.497 MeV / 0.134 MeV |
10 lines above the cutoff, and what each contributes
One further line below the 20 keV cutoff, at 9.11 keV with 3.04% emission probability, is excluded here and from Γ. Probability and dose share.
| Energy (keV) | Emission probability (%) | Share of dose rate (%) |
|---|---|---|
| 208.37 | 10.41 | 65.31 |
| 112.95 | 6.23 | 18.69 |
| 55.79 | 2.75044 | 5.88 |
| 54.61 | 1.5716 | 3.41 |
| 321.32 | 0.2186 | 2.27 |
| 63.33 | 0.90739 | 1.87 |
| 249.67 | 0.1997 | 1.55 |
| 64.94 | 0.24227 | 0.50 |
| 71.64 | 0.164 | 0.35 |
| 136.72 | 0.0465 | 0.17 |
0.404 mm of lead halves this spectrum
Solved numerically across all 10 lines, narrow beam. Why not one representative energy.
| Material | HVL (mm) | TVL (mm) | TVL / HVL |
|---|---|---|---|
| lead | 0.404 | 1.96 | 4.87 |
| tungsten | 0.302 | 1.47 | 4.86 |
| iron | 4.28 | 17.8 | 4.16 |
| copper | 3.42 | 14.7 | 4.28 |
| concrete | 20.6 | 72.2 | 3.51 |
| water | 46.9 | 159 | 3.39 |
| aluminum | 18.1 | 64.2 | 3.55 |
A single energy would give 3.32. Spectrum and attenuation ratios.
1.36 mm of acrylic stops the 0.497 MeV endpoint
Katz–Penfold fit to the 0.497 MeV endpoint — a stopping thickness rather than an attenuation length. Why the material matters more than the thickness.
| Absorber | Range for the endpoint (mm) |
|---|---|
| acrylic | 1.36 |
| aluminum | 0.601 |
| water | 1.62 |
| glass | 0.649 |
| Shield material | Fraction of beta energy converted to X-rays |
|---|---|
| acrylic (Z ≈ 6.5) | 0.11% |
| lead (Z = 82) | 1.43% |
Activity over days and weeks
Ten half-lives is 66.4 days — for Lu-177 itself, a storage problem rather than a disposal one, since those ten half-lives already take it below 0.1% of today's activity. The mean life 1/λ is 9.59 days.
| Elapsed | Fraction remaining |
|---|---|
| 1 half-life | 50.0 % |
| 2 half-lives | 25.0 % |
| 5 half-lives | 3.13 % |
| 10 half-lives | 0.0977 % |
| Time to fall to 10 % of today's activity | 22.1 days |
| Time to fall to 1 % | 44.1 days |
| Time to fall to 0.1 % | 66.2 days |
Limits of these dose rates
- 1.36 mm of acrylic for the 0.497 MeV endpoint: a fitted depth of penetration, not a skin dose.
- Air kerma, 1 µGy counted as 1 µSv — not H*(10).
- Model limits and internal dose.
Gamma, beta and decay calculators for Lu-177
- Gamma dose rate and shielding
- Beta dose rate and shielding
- Decay and half-life
- Mass and activity
- Detection limits (MDA / MDC)
- Remaining-activity table
- Worked example: a Lu-177 dose from calibration to storage
Other Lutetium nuclides: Lu-177m
Computed from the IAEA Nuclear Data Section — Livechart API (ENSDF) and the NIST X-Ray Mass Attenuation Coefficients. Derivations and citations.